HTR2A and Parkinson disease: The top 500 genes in the ranking contains 6 approved PD drug targets (including include COMT, DDC, DRD2, DRD3, HTR2A and MAOB), which is a 5.8-fold enrichment comparing with random rankings (p<e−4).